LENZ LENZ Corp: Accounting Value per Share

The development of unique presbyopia treatments is protected by patents, while FDA support creates a significant barrier to entry for competitors. The market trend for LENZ Therapeutics, Inc. (LENZ) reflects asset dynamics where the indicator stands at 6.99. The business relies on a streamlined component supply system, ensuring high profitability. However, challenges regarding the certification of new products and uncertainty in consumer demand may arise.

LENZ Therapeutics Inc (LENZ): Share Book Value from 03/23/2024 to 10/28/2026

lenz-tx.com - analytical breakdowns and key metrics (LENZ)

- price and consensus price forecast:

Price Chart LENZ Pharma|LENZ - Broker Consensus Forecast

- market capitalization data:

Market Valuation LENZ Therapeutics, Inc.|LENZ - Full Business Value

- book capitalization data:

Net Assets per Single Share LENZ Therapeutics|LENZ - Net Asset Value|Market Capitalization to Book Value Ratio lenz-tx.com|LENZ - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital LENZ Therapeutics, Inc.|LENZ - Long-Term Debt to Capital|Short-Term Debt to Equity LENZ Therapeutics|LENZ - Aggregate Debt Obligations|Debt to Book Capitalization Ratio LENZ Therapeutics, Inc.|LENZ - Company Long-Term Liabilities|Company Short-Term Debts LENZ Therapeutics

Fundamental company valuation:LENZ Pharma - LENZ

Manufactured products of LENZ Therapeutics

Book value per share reflects the portion of equity attributable to a single security upon the liquidation of the company. This metric is calculated by dividing total net assets by the total number of shares outstanding. By analyzing the growth rate of book value per share, an investor determines the actual intrinsic value of the business. For LENZ Therapeutics, Inc. (LENZ), this indicator confirms capital expenditures for the modernization of sterile lines and laboratories. Such infrastructure investments directly impact the fundamental valuation of assets.

Competitors of LENZ Therapeutics, Inc. (LENZ)

Alcon Vision (ALC) - Net Assets per Single Share|Bausch Health (BLCO) - Equity per Share|Accounting Value per Share Glaukos Corporation (GKOS)|APLS (apellis.com) - Share Book Value|Net Assets per Single Share belitebio.com BLTE|Share Book Value Ocular Therapeutix Inc|Harrow Health (HROW) - Book Value per Share|Accounting Value of a Share Viridian Corp (VRDN)|Book Value per Share OCS (Oculis AG)|eyepointpharma.com - Book Value per Share|Net Assets per Single Share Kodiak Sciences (KOD)|ALDX: Accounting Value of a Share|KALA (kalarx.com) - Net Assets per Single Share|Opus Genetics (IRD) - Accounting Value per Share|OKYO (OKYO Pharma Ltd) - Book Value per Share|Book Value per Share Adverum (ADVM)|Outlook Therapeutics, Inc. (OTLK) - Accounting Value per Share|Accounting Value of a Share Clearside Biomedical Inc (CLSD)|NBY: Book Value per Share|KPRX - Net Asset Value per Share|ALIM (Alimera) - Accounting Value per Share|EYEN - Net Asset Value per Share|Book Value per Share GHSI|OCUP (Ocuphire Pharma Inc) - Net Asset Value per Share|OPT: Net Assets per Single Share